PTC Therapeutics | PTCT - Operating Profit


PTC Therapeutics reported $-81.62M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025